“We continue to secure contracts with leading US hospital systems, reinforcing our position as the trusted vendor of choice in the rapidly evolving technology landscape. Contracts like this one not only affirm our industry leadership in the US market but also the dedication and expertise of our clinical and commercial teams. As hospitals now adhere to new practice recommendations mandating quantitative neuromuscular monitoring, being the only vendor with a portfolio of guideline-compliant solutions for adults, children, and patients with sensitive and fragile skin puts us in an exciting pole position,” commented Philip Siberg, CEO of Senzime.
 
Each year, approximately 100 million patients, including children, receive neuromuscular blocking drugs as part of anesthesia to facilitate endotracheal intubation and optimize surgical conditions. These medications paralyze muscles required for breathing, making accurate monitoring during surgery essential for ensuring each patient receives the appropriate dose for a safe and timely recovery.
 
Senzime’s TetraGraph is a state-of-the-art quantitative train-of-four monitoring system used at hundreds of leading hospitals worldwide. Its proprietary technology helps anesthesiologists in accurately selecting the correct dose of neuromuscular blocking drugs and their antagonists and determining when patients have safely recovered post-surgery.